Genscript Biotech stock

1548 · HKEX · HKD

Compare Genscript Biotech
$27.76Change from previous close: −7.96%Absolute change: −$2.40

Close · November 20, 2026

Price history

+74.81% over the period

1 year: from $15.88 (November 20, 2025) to $27.76 (November 20, 2026), +74.81%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026$27.76
October 30, 2026$35.02
September 30, 2026$44.86
August 31, 2026$33.88
July 31, 2026$18.06
June 30, 2026$12.23
May 29, 2026$13.68
April 30, 2026$13.72
March 31, 2026$10.95
February 27, 2026$11.94
January 30, 2026$12.85
December 31, 2025$12.39
November 28, 2025$14.91
November 20, 2025$15.88

At a glance

  • The company

    Manufacture and sale of life science research products and services, biologics development services, and industrial synthetic biology products

  • Latest results

    Quarter to June 30, 2026 · EPS -$0.06

TickerLandia's take on Genscript Biotech

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$10.36
52-wk high$49.46

−43.87% from the 52-week high

Analysts · 7 analysts

Average target$45.43+63.64% vs. price

Buy 7 · Hold 0 · Sell 0

TickerLandia Fingerprint: Genscript Biotech

Compared with similar companies: very strong momentum.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Genscript Biotech is pricier than similar companies

Genscript Biotech's Forward P/E: 76.9, +142% against the median of a group of 10 similar companies (31.7).

Compared with 10 similar companies

Genscript Biotech's metrics compared with similar companies
MetricGenscript BiotechPosition in the groupBand
Forward P/E76.9High
Operating margin14.9%Middle
ROE-15.3%Low
Debt/equity0.09Middle
Price/book2.16Low

Grey band: the middle half of the group; tick: the median; dot: Genscript Biotech. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$404.22M

Latest quarter · Q2 2026

Net income

-$129.34M

Latest quarter · Q2 2026

Quarterly net margin

-32.0%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$68.78B
EPS
-$2.29
Volume
20.25M
Daily trading
€160.12M

How Genscript Biotech is changing

All results
  • Revenue grew 19.7% a year on average over the last 5 years

  • Operating margin rose from −70.0% to 26.6%

  • Less cash than profit: free cash flow equal to -18% of net income

Returns

Genscript Biotech returns with dividends

$1,000 invested in Genscript Biotech 5 years ago, on November 22, 2021, would be worth $747 today with dividends reinvested: −25.28% in total, −5.67% per year. On price alone it would be $747 (−25.28%).

PeriodGenscript BiotechHang Seng$1,000 becomes
1 month−16.94%−6.10%$831
6 months+112.07%−12.63%$2,121
Year to date+124.05%−12.56%$2,241
1 year+74.81%−13.26%$1,748
3 years+16.39%+26.06%$1,164
5 years−25.28%−10.18%$747
10 years+631.16%+0.24%$7,312

Over the last 6 months it has done better than 100% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. Hang Seng: price only. Calculate your investment

The chart in detail

Genscript Biotech: technical analysis

Genscript Biotech shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 43.5% below its all-time closing high ($49.14, October 6, 2026).

Trend
No clear trend
RSI (14 sessions)
39
Between 30 and 70
vs 200-session average
+32.29%

Active signals

  • Close below the low of the previous 55 sessions.

  • The last session opened more than 3% below the previous close.

Support and resistance

Price areas where Genscript Biotech has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$28.49+2.63%2 touches, last on November 6, 2026
  2. Last price$27.76
  3. Support$15.15−45.44%6 touches, last on June 3, 2026
  4. Support$11.82−57.41%11 touches, last on June 22, 2026

Volatility and risk

Over the last year it has moved roughly in line with the Hang Seng.

Beta (1 year) vs Hang Seng
1.17
Volatility (60 sessions, annualised)
106.2%
Largest fall in the last year
−43.51%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Genscript Biotech: seasonality

Average monthly price change over 11 years

+0.0%Jan+7.6%Feb−6.1%Mar+5.8%Apr+6.2%May+3.0%Jun+11.2%Jul+17.2%Aug−3.6%Sep+6.7%Oct+4.5%Nov+4.2%Dec

Over the last 11 years, the strongest month for Genscript Biotech has been August: +17.16% on average, positive in 5 years out of 11. The weakest has been March: −6.06% on average, positive in 5 years out of 11. November, the current month, has been positive in 6 years out of 10 (+4.51% on average).

Show chart data
MonthAverageMedianPositive years
January+0.05%+3.71%7 of 11
February+7.57%+16.00%6 of 11
March−6.06%−2.83%5 of 11
April+5.79%+6.18%6 of 11
May+6.17%−0.29%5 of 11
June+3.04%+1.62%6 of 11
July+11.22%+5.04%7 of 11
August+17.16%−4.98%5 of 11
September−3.59%−2.79%5 of 11
October+6.73%+9.93%6 of 11
November+4.51%+2.02%6 of 10
December+4.17%−8.10%3 of 10

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Genscript Biotech and its competitors

Operating with 6,135 employees, Genscript Biotech Corporation works in three areas: life science research products and services, biologics development and industrial synthetic biology. Its research range includes SurePAGE precast gels, CytoSinct cell isolation products, eZwest Lite western blotting devices and GenBox electrophoresis tanks, used in life-science research. The biologics unit helps biopharmaceutical and biotech companies develop therapeutic antibodies and gene and cell therapy products, while the industrial unit makes enzymes through non-pathogenic microbial strains.

Headquarters
Wan Chai, Hong Kong
Employees
6,135
Founded
2002
Chief executive
Weihui Shao
Genscript Biotech and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Genscript Biotech1548$8.77B14.9%—+112.07%
Haisco Pharmaceutical Group002653$8.97B21.1%44.1+0.54%
ALTEOGEN196170$9.05B47.2%97.1−36.93%
Pharmaron Beijing300759$10.59B14.0%39.3+44.36%
Akeso9926$6.81B-30.7%—−50.70%
Sino Biopharmaceutical1177$11.65B28.2%34.2−1.26%

Same industry or related industries, similar size. Compare Genscript Biotech with its competitors · Full profile